NCT06618300
Streamlined Resin Y90 Radiation Segmentectomy for Small HCC
Enrolling by Invitation
Not specifiedAges 18+ObservationalUNC Lineberger Comprehensive Cancer CenterInvestigator-initiated
~30 participants
Updated 2025-11-17 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The treatment timeline
Measured over 3 days
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesNorth Carolina1
Study leadership
- Hyeon Yu, MD, FSIR · PRINCIPAL_INVESTIGATOR · UNC Department of Radiology
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
18 years of age or older
Has focal Hepatocellular Carcinoma and is deemed to benefit from Yttrium-90 radioembolization by the institutional multidisciplinary tumor board
Exclusion
The presence of trans-jugular intrahepatic portosystemic shunt
Total bilirubin level \> 3.0 mg/dL
Serum albumin level \< 2.5 g/dL
Aspartate and alanine aminotransferase levels no greater than five times the normal level
Life expectancy \< 12 weeks
Eastern Cooperative Oncology Group performance status \> 2
Patients with chronic lung disease requiring supplemental oxygen at baseline or baseline SpO2 of \<92%
Patients that have tumors with central anatomical locations close the hepatic hilum or caudate lobe.
Patients with macrovascular invasion on baseline imaging
Known hypersensitivity to iodinated contrast agents or to any component of iodinated contrast agents refractory to standard medications (antihistamines, steroids)
Impaired kidney function (glomerular filtration rate \< 30 as approximated using serum creatinine levels) unless anuric and on dialysis.
Any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine β-HCG results, obtained within 48 hours prior to the treatment or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of 1 year without menses)
What this trial measures
- The treatment timeline3 days
The treatment timeline will be measured in days from the date of the initial consultation of the patient in the interventional radiology clinic to the date of the Yttrium-90 (Y90) radioembolization procedure.
- Cumulative charges and reimbursement3 days
To observe cumulative charges and reimbursement for streamlined Yttrium-90 (Y90) radioembolization treatment, billing, and reimbursement information will be obtained through the billing department. The costs will be reported in US dollars.